Diabetes patients not getting full protection from standard aspirin dose
NCT ID NCT05702463
Summary
This study aims to find the best aspirin regimen for people with type 2 diabetes who don't respond well to standard low-dose aspirin. Researchers will test different doses and formulations (enteric-coated vs. chewable) in 30 participants to see which one most effectively prevents blood clots. The goal is to reduce heart attack and stroke risk in diabetes patients who may need personalized aspirin treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 2 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Montreal Heart Institute
RECRUITINGMontreal, Quebec, H1T 1C8, Canada
Contact
Conditions
Explore the condition pages connected to this study.